ライフサイエンスコーパス: agranulocytosis

1 ts use is limited by its potential to induce agranulocytosis.

2 cornerstone, but may cause life-threatening agranulocytosis.

3 d reversible neutropenia, but none developed agranulocytosis.

4 ability of 0.7% that a patient would develop agranulocytosis.

5 ating factor (GCSF) in levamisole-associated agranulocytosis.

6 of extrapyramidal side effects but may cause agranulocytosis.

7 remaining life expectancy after detection of agranulocytosis.

8 assumed a 20% mortality among patients with agranulocytosis, $30.61 in monitoring costs each week, a

9 dults with any non-chemotherapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9

10 The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x

11 t (albeit rare) adverse reactions, including agranulocytosis and hepatotoxicity.

12 hat can cause adverse side effects including agranulocytosis and liver damage.

13 ults could be useful for antithyroid-induced agranulocytosis and potentially for agranulocytosis caus

14 erases (two events in two patients, one with agranulocytosis), and decline in neurological functionin

15 One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; bot

16 utrophil counts below 0.5 x 10(9)/L, two had agranulocytosis, and four had recurrent infections.

17 To avoid one case of agranulocytosis, based on the possible risk reduction if

18 the drug adverse reaction, clozapine-induced agranulocytosis (CA), is associated with different HLA t

19 dy on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls

20 Agranulocytosis caused by levamisole exposure through co

21 -induced agranulocytosis and potentially for agranulocytosis caused by other chemicals.

22 nalysis with data from the Clozapine-Induced Agranulocytosis Consortium (up to 163 cases and 7970 con

23 Agranulocytosis developed in three patients in the cloza

24 I because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

25 not evidence-based because the incidence of agranulocytosis does not exceed that of conventional ant

26 d by utilizing cumulative incidence rates of agranulocytosis from a recent study with a large sample

27 s curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe advers

28 actory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively.

29 nts associated with antithyroid drug-induced agranulocytosis in a white European population.

30 fective because of the very low incidence of agranulocytosis in the later periods.

31 Hong Kong have shown an association between agranulocytosis induced by antithyroid drugs and the HLA

32 Agranulocytosis induced by non-chemotherapy drugs in gen

33 Drug-induced agranulocytosis is a potentially life-threatening advers

34 pine, although the incidence of drug-induced agranulocytosis is lower than previously expected.

35 Late-onset agranulocytosis is rare during treatment with clozapine,

36 Agranulocytosis occurred in 1.2 percent of the patients

37 mptoms, 4 had a rising serum ferritin, 3 had agranulocytosis or neutropenia, 1 had tachycardia, 1 had

38 tment did not induce additional weight gain, agranulocytosis, or seizures compared with clozapine/pla

39 gly associated with antithyroid drug-induced agranulocytosis: rs652888 (OR 4.73, 95% CI 3.00-7.44, p=

40 severely restricted due to hepatoxicity and agranulocytosis side effects associated with its long te

41 The authors describe a case of agranulocytosis that emerged after 19 years of continuou

42 39 of the 234 patients had agranulocytosis that was induced by antithyroid drugs (t

43 deepened our understanding of the levamisole-agranulocytosis vasculopathy syndrome.

44 cted probability of antithyroid drug-induced agranulocytosis was about 30% (OR 753, 95% CI 105-6812).

45 te European people, antithyroid drug-induced agranulocytosis was associated with HLA-B*27:05 and with

46 0 (3.81-13.96) when antithyroid drug-induced agranulocytosis was compared with population controls (p

47 The discovery of the agranulocytosis was due to the lifelong white blood cell